BusinessMedical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication Through American Chemical Society for KLS-13019, a Novel Cannabidiol-Derived Target Drug Candidate for Hepatic EncephalopathyBy Nasdaq OMXFeb 18, 2016, 2:00 PM UTC